Stifel Upgrades Biogen (BIIB) to Buy, 'Risk/Reward Shifting Favorably With Clinical Catalysts'
Tweet Send to a Friend
(Updated - November 6, 2025 5:08 AM EST)
Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
